DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Waibel M, Solomon VS, Knight DA. et al.
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Cell Rep 2013;
5 (04) 1047-1059
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.